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Abstract
Background: Treatment options for achalasia include endoscopic and surgical techniques that carry the risk of esophageal
bleeding and perforation. The rare coexistence of esophageal varices has only been anecdotally described and treatment is
presumed to carry additional risk.
Methods: Experience from physicians/surgeons treating this rare combination of disorders was sought through the
International Manometry Working Group.
Results: Fourteen patients with achalasia and varices from seven international centers were collected (mean age 61 9
years). Five patients were treated with botulinum toxin injections (BTI), four had dilation, three received peroral endoscopic
myotomy (POEM), one had POEM then dilation, and one patient underwent BTI followed by Heller’s myotomy. Variceal
eradication preceded achalasia treatment in three patients. All patients experienced a significant symptomatic improvement
(median Eckardt score 7 vs 1; p< 0.0001) at 6 months follow-up, with treatment outcomes resembling those of 20 non-
cirrhotic achalasia patients who underwent similar therapy. No patients had recorded complications of bleeding or
perforation.
Conclusion: This study shows an excellent short-term symptomatic response in patients with esophageal achalasia and
varices and demonstrates that the therapeutic outcomes and complications, other than transient encephalopathy in both
patients who had a portosystemic shunt, did not differ to disease-matched patients without varices.
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Introduction
Achalasia is a very uncommon primary motor disorder
of the esophagus characterized by incomplete relax-
ation of the lower esophageal sphincter (LES) and
impaired esophageal motility.1,2 This clinically presents
with symptoms of dysphagia, regurgitation, chest pain,
and/or weight loss. All current treatments aim at redu-
cing LES resting pressure with botulinum toxin injec-
tion (BTI), pneumatic dilatation, peroral endoscopic
myotomy (POEM), or Heller’s myotomy commonly
with a partial anti-reﬂux procedure.2
The presence of portal hypertension with varices is
inﬁnitely rarely reported to occur in conjunction with
achalasia and the choice of treatment in this context
represents a challenging therapeutic dilemma, even
in specialized centers. To the best of our knowledge,
12 cases reports have been described in the literature
with only eight patients having received treatment.3–13
The limitation of oral food intake and subsequent
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weight loss observed in achalasia will inevitably
have detrimental consequences in cirrhotic patients; sig-
niﬁcant weight loss and malnutrition could aggravate
pre-existing hypoalbuminemia, precipitating cirrhosis
complications (i.e. ascites and spontaneous bacterial
peritonitis) and expose patients to cachexia and/or vita-
min deﬁciency and its sequelae.14 Furthermore, persist-
ent food stasis and progressive esophageal dilatation
can increase the risk of esophagitis which could con-
ceivably increase the risk of inﬂammation, erosion and
ulcer formation and subsequent variceal bleeding. On
the other hand, all achalasia treatments themselves
carry the burden of complications, including bleeding
and full thickness esophageal perforation, the conse-
quences of which could be compounded, even life-
threatening, in patients with cirrhosis.15 Therefore, the
risks of the interventions must be carefully weighed
against the intended beneﬁts. Yet, due to the paucity
of published data and the rarity of this combination of
disorders, the therapeutic management and the out-
comes of diﬀerent treatment modalities have only
been anecdotally described. To this aim, we describe
the trends in therapeutic interventions undertaken in
the largest cohort of achalasia patients with varices
treated at tertiary care institutions around the world.
Methods
Study design
This is a retrospective, multicenter case-series of
patients with achalasia and concomitant esophageal
varices who received treatment at seven international
tertiary referral centers: University College Hospital
(UCH, London, United Kingdom), Royal Adelaide
Hospital (Australia), Washington University
(St Louis, USA), Edouard Herriot Hospital (Lyon,
France), University of Padova (Italy), University
‘‘Federico II’’ (Naples, Italy), and Amsterdam
Medical Centre (Netherlands). Experience from phys-
icians/surgeons treating this rare combination of dis-
orders was sought through the International
Manometry Working Group. As this was a retrospect-
ive assessment from multiple international centers,
acquiring consent was not possible; however, all patient
data were rigorously anonymized during the data col-
lection and analysis process.
Study patients
Achalasia patients with concomitant varices presenting
between 2008 and 2016 were retrospectively reviewed.
The pre-treatment evaluation of patients included
Eckardt score symptom assessment, endoscopic evalu-
ation, esophageal varices grading, barium swallow
and high-resolution esophageal manometry (HRM).16
Most cases were reviewed in multidisciplinary settings
and the decision of the type of treatment was endorsed
by weighing the individual risk-to-beneﬁt ratio on a
case-by-case basis. In all patients, a careful retrospect-
ive chart review was performed, recording variables
including age, gender, type of treatment, need for re-
intervention, treatment of esophageal varices and
timing of variceal eradication (i.e. pre- or post-achala-
sia treatment), etiology, and severity of concomitant
liver disease as assessed by the Child–Pugh score.17
The occurrence and type of any endoscopic and/or
post-endoscopic complications were also sought.
Prior to treatment, achalasia severity was assessed by
using the Eckardt score, according to previously stan-
dardized methods.18 Patients were followed up at one
and approximately 6 months after the initial treatment
and the symptomatic response was reassessed. In agree-
ment to that reported from previous studies, treatment
success was deﬁned as a decrease in the Eckardt scores
to less than 3.19 Twenty age-matched achalasia patients
without varices who were treated at UCH served as
disease-matched controls.
Statistical analysis
The data were entered into an anonymized database
and analysis was performed using SPSS (Statistical
Package of the Social Sciences) 10.0.1 for Windows.
The Eckardt score values are presented as median/
interquartile range (IQR) and the change in total
Eckardt score before and after treatment was compared
using paired Student’s t-test for parametric variables.
An -error 0.05 was considered as statistically
signiﬁcant.
Results
Patient demographics
Fourteen patients with achalasia and concomitant
esophageal varices were included (10 males; mean age
61 9 years). The etiology and stage of the underlying
liver disease, as well as the grade of the esophageal
varices, are depicted in Table 1. None of the patients
presented with hematemesis and/or melena or had a
history of upper gastrointestinal tract bleeding. The
grade of esophageal varices was classiﬁed using stan-
dardized criteria as follows: no varicose appearance
(F0), straight small-caliber varices (F1), enlarged
tortuous varices (F2), markedly enlarged, nodular vari-
ces (F3).20
As part of their diagnostic work-up, 10/14 (69%)
patients had a barium swallow and all but one had an
HRM study performed. Based on the HRM results,
2 United European Gastroenterology Journal 0(0)
patients were subcategorized as having type I
(4 patients), type II (6 patients), type III achalasia
(2 patients), and/or esophago-gastric junction outﬂow
obstruction (EGJOO) (2 patients), in accordance with
the Chicago classiﬁcation.21 One of the patients did not
tolerate pre-treatment manometry but the diagnosis
of advanced Type I achalasia was based on clinical,
endoscopic, endoscopic ultrasound (EUS), and radio-
logical ﬁndings. The median pre-therapy Eckardt score
was 7.8 (IQR 6–9). Table 1 summarizes the baseline
characteristics of the studied population.
Interventions
The decision of the type of treatment was often
endorsed by a multidisciplinary team, taking into
account the individual risk-to-beneﬁt ratio on a case-
by-case basis. Variables that impacted the decision-
making process for treatments included age, severity
of esophageal varices, pre-treatment symptom scores
(i.e. absence of signiﬁcant weight loss), baseline liver
function tests (i.e. coagulation abnormalities and/or
thrombocytopenia), one-year mortality risk of patients
based on the overall comorbidities and associated cir-
rhosis, as well as achalasia subtype and mucosal
disease. Three out of 14 patients (2 patients with F3
and 1 with F2 varices, respectively) underwent variceal
eradication prior to achalasia therapy with endoscopic
band ligation. In two patients with F3 varices, ligation
was followed by a trans-jugular intrahepatic portosys-
temic shunt (TIPSS). None of the other 11 cases had
variceal eradication in advance. Patients had a diverse
selection of achalasia treatments. Six patients (mean
age 63 6 years) were treated with BTI, one of which
under EUS guidance in attempt to avoid submucosal
and peri-esophageal collaterals. One patient in the BTI
group subsequently underwent Heller’s myotomy as
symptoms persisted at one-month follow-up. Five
patients (mean age 58 13 years) had pneumatic dila-
tion to at least 30mm. Finally, three patients (mean age
61 10 years) received POEM, one of whom required
subsequent pneumatic dilatation as symptoms persisted
at 1-month follow-up (see Figure 1).
Treatments outcomes
All patients exhibited a signiﬁcant symptomatic
improvement at 6 months follow-up of their ﬁnal pro-
cedure. The median post-intervention Eckardt score
was 1.3 (IQR 0–2; p< 0.0001), with an average
Table 1. Characteristics, treatment and outcomes of all 14 patients with achalasia and esophageal varices.
Case
no. Gender Age
Pre-treatment
Eckardt score
Varices
grade
Achalasia
subtype
Etiology
of liver
disease
Child–Pugh
Variceal
eradication
in advance
Type of
treatment
Post-treatment
Eckardt scoreScore
1 M 78 7 3 I NASH B7 Band ligation
& TIPSS
Pneumatic
dilatation
0
2 F 56 7 2 I alcohol A5 Band ligation Pneumatic
dilatation
2
3 M 66 5 1 III HCV A5 – EUS-guided BTI 2
4 M 60 9 3 I alcohol B9 Band ligation
& TIPSS
BTI 3
5 M 74 7 1 II alcohol B7 – BTI 0
6 F 63 7 1 II NASH A5 – BTI 0
7 M 57 10 1 I HCV B7 – BTI 4
8 F 60 10 1 EGJOO cryptogenic A6 – BTI then Heller’s
myotomy
0
9 M 47 6 1 II cryptogenic A6 – Pneumatic
dilatation
2
10 M 52 6 1 II alcohol A5 – Pneumatic
dilatation
1
11 M 51 9 1 II alcohol A5 – POEM 2
12 M 63 9 1 II alcohol A5 – POEM 0
13 M 71 9 1 EGJOO NASH A5 – POEM 1
14 F 66 9 1 I HCV A6 – BTI 0
NASH: non-alcoholic steatohepatitis; EGJOO: esophago-gastric outflow obstruction; TIPSS: trans-jugular intrahepatic portosystemic shunt; BTI: botulinum
toxin injection; POEM: peroral endoscopic myotomy.
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Eckardt score drop of 6.5 2.0 compared to baseline.
When considering the diﬀerent treatment modalities,
the changes in Eckardt scores were 5.8 1.6 in the
BTI group, 5.3 1 in the pneumatic dilatation group,
and 8.0 1 in the POEM group, respectively. The only
patient treated with Heller’s myotomy scored zero
6 months after surgery, with a change in Eckardt
score value of 10. All but one patient (in the BTI
group; Eckardt score 4) had a ﬁnal Eckardt score of
3 and were therefore considered as successfully trea-
ted. There were no complications related to bleeding or
perforation post-operatively. However, both patients
who underwent TIPSS developed a transient episode
of acute encephalopathy, which delayed the pneumatic
dilatation.
Twenty consecutive achalasia patients without vari-
ces (7 males, mean age 62.9 14.8) served as disease-
and age-matched controls. Table 2 summarizes the
baseline characteristics of the controls. There were no
signiﬁcant diﬀerences in the average change of Eckardt
score values (6.5 2.0 vs 6 1.1) or median post-
operative Eckardt scores at 6-month follow-up (1.3 vs
1.0 2.1) compared to baseline in patients with and
without varices, respectively. The choice of treatment
in disease-matched control patients without varices is
depicted in Table 2. Only a single patient in the control
group had undergone BTI as ﬁrst line therapy. In the
control group, one patient required pneumatic dilata-
tion following the POEM procedure, whilst another
had a subsequent Heller’s myotomy following incom-
plete relief after dilatation. Also, in the control group,
all but one patient had a signiﬁcant improvement
achieving a ﬁnal Eckardt score of less than three and
no diﬀerences were observed compared to the popula-
tion of achalasia patients with varices (see Figure 2).
Discussion
The case series presented describes the experience of
centers from around the world in investigating and
treating patients with the rare combination of achalasia
and esophageal varices. This study demonstrates
excellent outcomes in terms of complications and symp-
tomatic response, which did not diﬀer to those of a
disease-matched population of achalasia patients with-
out varices. However, it must be noted that the pres-
ence of varices and the presumed increased risk of
hemorrhage due to the underlying liver disease have
strongly inﬂuenced the therapeutic decision-making.
As compared to controls, in nearly 45% of the overall
population of achalasia patients with varices, BTI (with
or without EUS guidance) was the treatment of choice,
whilst only a single patient in the control group had
undergone BTI as ﬁrst line therapeutic intervention.
Although recognized as one of the most common
major esophageal motor disorders, achalasia represents
a rare condition with an estimated prevalence of 10 in
10,000 and an incidence rate ranging from 1.07 to up to
5 Botulinum toxin
injections
1 EUS guided
Botulinum toxin
injections
3 patients with
persistent
symptoms at
follow up
1 patient in the
botulinum toxin group
(1 month post treatment
Eckardt score 10) had a
subsequent Heller’s
myotomy
Watchful waiting
strategy for 1 patient in
the botulinum toxin
group (1 month post
treatment Eckardt score
4) as the risks
outweighed the benefits
1 patient in the POEM
group (1 month post
treatment Eckardt score
7) had a subsequent
pneumatic dilatation
All patients achieved
a significant
symptomatic relief
and all but one had
post-treatment
Eckardt score < 3
6 month follow up
5 Pneumatic dilatations
3 pre-oral endoscopic
myotomies
1 month follw up
Figure 1. Selection of treatments used in the whole cohort of patients with achalasia and varices. At 1-month follow-up, three patients
had persistent symptoms, two of whom were in the botulinum toxin group and one in the POEM group. One patient (Eckardt score 10)
underwent Heller’s myotomy and one patient (Eckardt score 7) had a subsequent pneumatic dilatation. The remaining patient had a
partial symptomatic relief (Eckardt score 4) not limiting oral food intake.
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2.8 new cases per year per 100,000 population.22,23 The
coexistence of esophageal varices with achalasia is
therefore inﬁnitely rare, and to the best of our know-
ledge, is described in literature in only a small number
of isolated case reports.3–13 A common presenting
symptom of achalasia is restricted caloric intake and
subsequent weight loss. Malnutrition in patients with
cirrhosis is of concern, ranging from 50% up to 90%,
rising alongside Child–Pugh score.24–26 In a large,
nationwide analysis of cirrhotic patients, malnutrition
has been associated with an increased incidence of com-
plications including ascites, reduced survival, worsening
hepatic function as well as risk of variceal bleeding and
surgical morbidity and mortality.26,27 This suggests that
the consequence of further reduction in oral intake
related to esophageal achalasia will compound the
risk further, potentially impacting on the long-term sur-
vival of patients. On the other hand, therapeutic inter-
ventions for achalasia carry a risk of esophageal
bleeding and perforation, the consequences of which
can be compounded by the coexistence of cirrhosis,
especially considering the increased risk of hemorrhage,
thrombocytopenia and coagulopathy.28
All achalasia interventions have risks and beneﬁts
and the choice of therapy normally depends on the
availability of local expertise as well as patient
choice;29 however; with the additional complexity of
having portal hypertensive disease and varices, this
decision needs to be carefully measured. Treatment
options presented in this case series of 14 patients
with achalasia and varices include BTI, pneumatic dila-
tation, surgical or endoscopic myotomy. Older patients,
with their increased burden of comorbidities, pre-
existing coagulopathy and/or thrombocytopenia have
been successfully treated with BTI. The beneﬁt of
using EUS to guide therapy is not clear and previous
case reports have suggested that EUS guidance could
conceptually prevent the risk of inadvertent injection of
toxin into the varices and can help avoid submucosal
and peri-esophageal collaterals.5,6 Yet, in this cohort,
only one patient had EUS-guided BTI with no diﬀer-
ence in terms of outcome or complications observed
Table 2. Baseline characteristics of achalasia patients with eso-
phageal varices (n¼ 14) and controls without varices (n¼ 20). In
the control group, one patient treated with POEM subsequently had
to undergo a pneumatic dilatation in order to achieve a good
symptomatic relief, whilst a patient who had pneumatic dilatation
subsequently preceded to having a Heller’s myotomy.
Achalasia with
varices (n¼ 14)
Achalasia without
varices (n¼ 20)
Gender (males, n (%)) 10 (71%) 7 (35%)
Age (mean SD) 61 9 years 62 14 years
Pre-treatment Eckardt
score (mean SD)
7.7 1.6 7 1.9
Etiology of liver disease
Alcohol, n (%) 7 (50%) –
Hepatitis C, n (%) 2 (14%) –
Cryptogenic, n (%) 2 (14%) –
Non-alcoholic
steatohepatitis, n (%)
3 (21%) –
Child–Pugh class
A, n (%) 10 (75%) –
B, n (%) 4 (25%) –
Varices grade
F1, n (%) 9 (64%) –
F2, n (%) 3 (21%) –
F3, n (%) 2 (14%) –
Achalasia subtypes
Achalasia type I, n (%) 3 (23%) 7 (35%)
Achalasia type II, n (%) 6 (46%) 10 (50%)
Achalasia type III, n (%) 2 (15%) 2 (10%)
OGJ outflow obstruction,
n (%)
2 (15%) 2 (10%)
Treatment selection
Pneumatic dilatation,
n (%)
5 (35%) 11 (55%)
Peroral endoscopic
myotomy, n (%)
3 (21%) 8 (40%)
Heller’s myotomy, n (%) 1 (7%) 1 (5%)
Botulinum toxin
group, n (%)
6 (43%) 1 (5%)
15
9
3
0
Pre-treatment Post-treatment
Varices
No varices
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Figure 2. Mean pre- and 6 months post-treatment Eckardt score
in the population of achalasia patients with varices (n¼ 14)
compared to age and disease matched controls (n¼ 20). All
patients displayed a significant reduction in Eckardt scores fol-
lowing treatment (at least a 2-point decrease compared to base-
line). All but one patient in both populations had a 6-month
Eckardt score 3.
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compared to the others in the BTI group. The literature
conﬁrms that although BTI can exhibit a good symp-
tomatic response in the short-term, it does not halt pro-
gression of achalasia, with less than 50% of treated
patients maintaining a good response at one year.30
In our series, one of BTI-treated patients subsequently
required a Heller’s myotomy; however overall, at short
term follow-up of 6 months, only one patient had a
suboptimal symptomatic response with an Eckardt
score that remained above 3.
In younger patients, with lower grade varices and
well-compensated liver cirrhosis, other therapeutic
modalities can be undertaken safely. In this series,
ﬁve of the 14 patients underwent pneumatic dilation
to at least 30mm diameter, while four had surgical or
endoscopic myotomy with no bleeding or perforation
complications described.
It is not clear if variceal eradication should be under-
taken in advance, and if so, if this should be with super-
ﬁcial eradication with band ligation and/or with
diversion of portal ﬂow with TIPSS. On one hand, vari-
ceal eradication might conceptually reduce the risk of
bleeding, while on the other hand, it has been advo-
cated that band ligation prior to achalasia treatment
might induce esophageal scarring and, in turn, worsen
the dysphagia;4 however, in this series, there did not
appear to be any diﬀerence in treatment outcomes in
the patients who had band ligation prior to achalasia
treatment (2 F2 and 1 F3 varices patients) compared to
those who did not. In both patients who had TIPSS,
there was a transient period of encephalopathy.
Although POEM is increasingly being advocated as
ﬁrst line therapy in many institutions, even in the eld-
erly,31 the additional consequence of varices, portal
hypertension and comorbidities associated with cirrho-
sis is likely to inﬂuence therapeutic decision-making.
This is indeed reﬂected in our cohort as only 21% of
patients in the varices group underwent POEM com-
pared to 40% in the controls.
Recent studies have shown that the 2- and 5-year
outcomes following sequential pneumatic dilatation
and laparoscopic Heller’s myotomy are comparable,
with a random-eﬀects model risk ratio of 1.05 and
1.17 (p¼ 0.49 and 0.34 at 2 and 5 years follow-up,
respectively).32 However, as shown by a recent meta-
analysis, esophageal perforation rates after laparo-
scopic Heller’s myotomy were lower than balloon
dilation (0.8% vs 4.9%), and during long-term
follow-up (>6 years), nearly 25% of patients required
repeated dilatations.30,33,34 This might compound the
likelihood of potential complications with repeated
invasive therapies in the context of concomitant
Consider variceal eradication prior to
achalasia treatment, weigh the individual
risk-to-benefit ratio, surgeons and
endoscopists expertise, multidisciplinary
evaluation
Younger patients, lower
number of comorbidities,
well compensated liver
disease, higher general
anaesthesia risk
Consider pneumatic
dilatation
Esophageal achalasia
with varices
Careful history taking,
consider cirrhosis etiology
and comorbidities, evaluate
general anaesthesia risk
Evaluate nutritional status.
Consider bridging therapy with enteral and/or
parenteral nutrition.
Older patients, high
number of comorbidities,
preexisting coagulopathy
or thrombocytopenia, low
1-year survival rare
Consider botulinum
toxin injections ±
EUS guidance 
Esophageal varices
grading
Achalasia treatment ±
previous variceal
eradication
Younger patients, lower
number of
comorbidities, low 1-
year mortality rate, low
general anaesthesia risk
Consider POEM or Heller’s
myotomy based on the
centre expertise
Figure 3. Proposed therapeutic algorithm in patients with esophageal achalasia and varices. All treatment modalities offer benefits and
can involve risk. The therapeutic choice should be endorsed by a careful multidisciplinary evaluation of the individual risk-to-benefit ratio
based on the center’s expertise.
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varices and suggests that in patients with a favorable
long-term survival based on the underlying liver dis-
ease with a low general anesthesia risk, it might be
reasonable to consider single therapy, with surgical or
endoscopic myotomy.34 Based on this presumption, a
suggested modiﬁed therapeutic algorithm for patients
with achalasia and concomitant varices is presented in
Figure 3. However, it is important to underline that
these recommendations are based on experts’ opinion,
and caution should always be exercised when
managing these patients, taking into consideration
the theoretical risks of complications, preferably with
the therapeutic decision-making being undertaken
within a multidisciplinary setting with all relevant
professionals.
This study has several limitations that merit discus-
sion. First, this is a retrospective case-series conducted
over several years in tertiary referral centers. It there-
fore reﬂects the local expertise and experience in treat-
ing achalasia. Secondly, nearly 65% of subjects had low
grade varices (F1) which might at least partially explain
the absence of serious adverse events and/or major
bleeding episodes. It is also possible that there was
underlying reporting bias and that patients with favor-
able outcomes were preferentially volunteered for inclu-
sion into this series. Furthermore, the decision for
therapy was not standardized and not every treatment
was based upon multidisciplinary discussion. Finally,
the follow-up period is short (6 months), so no deﬁnite
conclusions about the long-term therapeutic outcome
can be drawn. Longer follow-up information was not
possible as acquisition of patient information was
based on a retrospective search from various inter-
national institutions, and beyond 6 months many
patients were lost to contact, discharged, or deterio-
rated due to the underlying liver disease which either
precluded further therapy or led to patient demise.
Nonetheless, to the best of our knowledge, we herein
report for the ﬁrst time the outcomes of the largest
population of patients with achalasia and varices. Our
results suggest that, at least in the short-term, all treat-
ment modalities can be safely considered with symp-
tomatic outcomes mirroring those of standard
achalasia without varices. It appears therefore that des-
pite the presence of varices, all conventional achalasia
treatments are safe and eﬀective, provided that the
interventions are performed in the specialized settings.
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